Lakeside Holding Ltd 3Q 2026: Revenue $1.33M, Net income $142K — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Lakeside Holding Ltd reported Q3 2026 revenue of $1.33M, a 167% increase from $497K YoY, and net income of $142K, reversing a $1.071M loss from the previous year. Pharmaceutical sales surged 614% year-to-date, with active customers rising from 8 to 14. Infusion products accounted for 93% of sales, though gross margin declined. The company reclassified ABL Chicago as discontinued operations to focus on pharmaceutical distribution.
Lakeside Holding Ltd reported third-quarter 2026 results showing a sharp year-over-year improvement as revenue rose to $1.33M and the company turned profitable with net income of $142K, compared with $497K revenue and a $1.071M loss in the year‑ago quarter.
Financial Highlights
- Revenue was $1.33M for Q3 2026, up from $497K in the year‑ago quarter; YoY change 167.0%.
- Net income was $142K for Q3 2026, versus a net loss of $1.071M in the year‑ago quarter (turned profitable YoY).
Business Highlights
- Pharmaceutical revenue growth accelerated, with continuing pharmaceutical sales up roughly 614% year to date, driven by expansion of infusion products and new customers.
- Active customers increased from 8 to 14 over the nine‑month period; sales are primarily to hospitals and distributors through agents, lifting order volumes.
- Infusion products comprised about 93% of sales; gross margin declined due to reduced supplier rebates despite higher volumes.
- The company disposed of ABL Chicago on Feb. 12, 2026, reclassifying it as discontinued operations to concentrate on pharmaceutical distribution growth.
- Working capital and liquidity were affected by a large third‑party loan receivable and higher prepayments, concentrating current assets and impacting operating cash flow.
Original SEC Filing: Lakeside Holding Ltd [ LSH ] - 10-Q - May. 19, 2026